培美曲塞联合卡铂治疗非小细胞肺癌40例临床观察.pdfVIP

792 中国肿瘤临床2013年第40卷第13期 ChinJClinOncol2013,Vol.40,No.13 培美曲塞联合卡铂治疗非小细胞肺癌40例 临床观察 朱 斌 苗晓慧 培美曲塞（PEM）是一种多靶点抗叶酸化疗药，目前已成为晚期非小细胞肺癌二线治疗的标准药物。本研究回 摘要 目的： 顾分析培美曲塞联合铂类治疗非小细胞肺癌的临床疗效及不良反应。 选择经病理学证实的非小细胞型肺癌患者40例，予 方法： 2 以培美曲塞二钠500mg/m静脉滴注，联合卡铂常规剂量第1d、21d为1周期，每例患者至少化疗2个周期（观察组），并与吉西他滨 （GEM）+卡铂方案做对照（对照组），评价疗效及不良反应。 治疗2个周期后PEM组有效率50%，GEM组有效率45%。主要 结果： 为骨髓抑制及胃肠道反应，PEM组的骨髓抑制、胃肠道反应、AST、尿素氮及皮疹、脱发的发生率明显低于GEM组，2组不良反应 比较差异有统计学意义（P0.05）。结论：培美曲塞二钠联合卡铂治疗非小细胞型肺癌临床疗效明显，不良反应少。 关键词 培美曲塞 卡铂 非小细胞型肺癌 doi:10.3969/j.issn.1000-8179.2013.13.011 Clinical trials of pemetrexed combined with carboplatin in treating 40 non-small cell lung cancer patients Bin ZHU, Xiaohui MIAO Correspondence to: Bin ZHU; E-mail: drzhubin@163.com Department of Thoracic Surgery, Tianjin Haihe Hospital, Tianjin 300350, China. Abstract Objective: Pemetrexed (PEM) is a multi-targeted chemotherapeutic agent for antifolate drugs. PEM has become the standard agent for the second-line treatment of advanced non-small cell lung cancer (NSCLC). This study aims to review and analyze the clinical efficacy and adverse reactions of PEM combined with carboplatin with respect to NSCLC treatment. Methods: A total of 40 patients suffering from NSCLC were selected and confirmed by pathology. On the first day of treatment, the conventional 500 mg/m2 dose of pemetrexed disodium was infused intravenously. On the second day, a combined therapy with carboplatin was conducted based on the conventional dose for a 21-day cycle with at least two cycles for each patient. The therapeutic efficacy and adverse reactions were evaluated and were compared with the proposed